EL-24· Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
EL-24 · Reference data
GHRH-Analog · 44-AS-Peptid
Aliases: TH9507 · Egrifta
| Molecule | Tesamorelin (TH9507) |
| Sequence | [Trans-3-hexenoyl]-GHRH(1-44)-NH2 |
| CAS | 218949-48-5 |
| Molecular weight | 5.196 kDa |
| Form | Lyophilized powder |
| Strength per vial | 5 mg, 10 mg, 20 mg |
| Box contents | 10 vials of identical strength |
| Purity | ≥99 % (HPLC) |
Tesamorelin is a GHRH analog whose sequence is modified by a hexenoyl group. In research it binds GHRH receptors and is studied in endocrine cell models for signal transduction and the GH axis. The modified sequence increases stability relative to the natural GHRH fragment. Typical questions address receptor affinity, downstream signalling and the regulation of the GH axis at the cellular level. As a reference compound, tesamorelin allows different experimental approaches to be compared within a defined assay system. Researchers who buy Tesamorelin use this 10-vial kit as a defined reference for in-vitro work.
The lyophilized powder is reconstituted in the laboratory with a suitable sterile solvent. The solvent is added slowly along the vial wall and the preparation is mixed gently until the powder has dissolved completely. The resulting solution is processed promptly and protected from direct light until use. Volume or concentration figures are not part of this description; those parameters are set by the receiving laboratory's own protocol.
In in-vitro research, tesamorelin serves as reference material for binding studies at the GHRH receptor. Endocrine cell models use the peptide to investigate signal transduction along the GH axis and the downstream cellular responses. Comparative assays that set the GHRH analog against the natural fragment also benefit from the increased stability of the modified sequence. The favourable solubility of the lyophilized powder simplifies the preparation of defined dilution series for concentration-response curves.
Every lot of tesamorelin is tested for purity by HPLC; the content is ≥99 %. An identity check additionally confirms the modified GHRH sequence of the molecule. Results are documented per lot and apply uniformly to both available strengths. This analytical characterisation provides a reliable basis for comparing data series and for the reproducibility of in-vitro experiments.
Available amounts per vial: 5 mg, 10 mg, 20 mg. Box of 10 vials.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
For research use only. Not for human or animal use, diagnosis, therapy or consumption.
A box contains exactly 10 identical, unlabelled vials of the selected variant. The product label is on the outer box.
Available amounts per vial: 5 mg, 10 mg, 20 mg.
5-Amino-1MQ
AHK-Cu
AOD-9604
B12
BAC Water 10 ml
BPC-157
Cagrilintide 5 mg
CJC-1295 (Mod GRF 1-29)
